CellSeedCellSeed Inc.7776東証グロース精密機器FY ending Dec 2025, non-consolidated, J-GAAP
About 91% of CellSeed's sales come from Laboratory consumables and equipment, with Cell-Sheet regenerative medicine making up much of the rest.
It lost about ¥535 for every ¥100 of sales at the operating level.
Revenue changed -18.9% from the prior year.
FY ending Dec 2020 → FY ending Dec 2021
FY ending Dec 2020 → FY ending Dec 2021
For every ¥100 CellSeed sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.